Global Opioid Induced Constipation Drugs Market is expected to reach USD 2,779.24 Mn by 2022- Acute Market Reports

“Acute Market Reports Logo” has Published New Research Report Title”Global Opioid Induced Constipation Drugs Market”

“Opioid Induced Constipation Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022, the opioid induced constipation drugs market was valued at USD 1,933.2 Mn in 2015, and is expected to reach USD 2,779.24 Mn by 2022, expanding at a CAGR of 4.6% from 2016 to 2022.

For Complete Report Visit@

Market Insights
Alarming growth in opioid prescription for non-cancer pain has been a phenomenal event in the previous decade. As per the recent estimates, more than 40% of opioid consumers experience constipation and GI symptoms as side effects of opioid drugs. Rising pool of opioid users will lead to the growth in opioid induced constipation (OIC) prevalence thus contributing to OIC drugs market growth. The global opioid induced constipation drugs market was valued at USD 1,933.2 Mn in 2014 and is expected to reach USD 2,779.2 Mn by 2022 with the market growing at a CAGR of 4.6% during 2016-2022.
Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated for OIC treatment. Among these, methylnaltrexone bromide holds the largest market size and is expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone under the brandname Amitiza is indicated for treating OIC, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over the market share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for various patient types such as pregnant women and patients less than 17 years of age. Thus, future approvals are expected to lead the market.
North America is the dominant regional OIC drugs market through the forecast period. Early bird approval of OIC drugs by the USFDA and high consumption of opioids in the US are the prime growth factors for the OIC drugs market in North America. On the other hand, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of OIC drugs.
On the basis of prescription type the market is segmented into prescribed drugs and over the counter or OTC drugs. Constipation is never considered as a disease but a syndrome or a side effect; people are less likely to visit doctors to get prescription for constipation. Thus, the OIC drugs market is dominated by over the counter prescription with 65.87% market share in 2014. The OTC drug market will continue to dominate the market growing at the highest CAGR of 4.9% during 2016-2022.”

Chapter 1 Preface
1.1 Report Scope and Description
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Opioid Induced Constipation (OIC) Drugs Market Industry Snapshot

Chapter 3 Global OIC Drugs Market Analysis
3.1 OIC Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers Increasing Use of Opioid Elderly Population

Browse For Complete Report With TOC Visit@ Rising Opioids Prescription in North America and Europe Large Range of Effective OIC Drugs Available
3.3.2 Restraints Research on Pain and Next Generation Analgesics Adverse Effects of OIC Drugs Unawareness and hesitation among patients Large number of considerations while using opioids
3.3.3 Opportunities Emerging APAC Market Rising Use of Opioids
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key OIC Drugs Manufacturers

Chapter 4 Global OIC Drugs Market, by Drug Type
4.1 Overview
4.2 Methylnaltrexone Bromide
4.3 Lubiprostone
4.4 Naloxegol
4.5 Pipeline Drug Analysis: Phase 3: Naldemedine (Year of Launch to 2022 (USD Mn)
4.6 Pipeline Drug Analysis: Phase 3: Elobixibat (Year of Launch to 2022 (USD Mn)
4.7 Pipeline Drug Analysis: Phase 2: Alvimopan, Dolcanatide (Qualitative Information)

Chapter 5 Global OIC Drugs Market, by Prescription Type
5.1 Overview
5.2 Prescribed Drugs
5.2.1 Prescribed OIC Drugs Market, by Prescription Type 2014-2022 (USD Mn)
5.2.2 Prescribed OIC Drugs Market, by Prescription Type, 2014-2022 (USD Mn) Prescribed Branded OIC Drugs Market 2014-2022 (USD Mn)
5.2.3 Over the Counter Drugs………

About – Acute Market Reports:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.

Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.



Visit Our Blogs@

Browse For Same Category Report:


Media Contact
Company Name: Acute Market Reports
Contact Person: Chris Paul
Phone: India: +91 7755981103, Toll Free US/Canada: +1-855-455-8662
Address:Office No 01, 1st Floor, Aditi Mall, Baner
City: Pune
State: Maharashtra
Country: India